Список литературы

Основные статьи

American Diabetes Association. Standards of medical care in diabetes - 2017. Diabetes Care. 2017;40(suppl 1):S1-S135.Полный текст external link opens in a new window

Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.Полный текст external link opens in a new windowАннотация external link opens in a new window

Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740-751.Аннотация external link opens in a new window

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-65.Аннотация external link opens in a new window

Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.Полный текст external link opens in a new windowАннотация external link opens in a new window

Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.Аннотация external link opens in a new window

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.Полный текст external link opens in a new windowАннотация external link opens in a new window

Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.Полный текст external link opens in a new windowАннотация external link opens in a new window

Статьи, указанные как источники

1. Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes. 2003;52:1475-1484.Полный текст external link opens in a new windowАннотация external link opens in a new window

2. American Diabetes Association. Standards of medical care in diabetes - 2017. Diabetes Care. 2017;40(suppl 1):S1-S135.Полный текст external link opens in a new window

3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.Полный текст external link opens in a new windowАннотация external link opens in a new window

4. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787-835.Аннотация external link opens in a new window

5. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514-1523.Полный текст external link opens in a new windowАннотация external link opens in a new window

6. Wormser D, Kaptoge S, Di Angelantonio E, et al; Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377:1085-1095.Аннотация external link opens in a new window

7. National Diabetes Data Group. Diabetes in America. 2nd edition. NIH Publication No. 95-1468. January 1995. http://diabetes.niddk.nih.gov/ (last accessed 17 July 2017).Полный текст external link opens in a new window

8. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.Полный текст external link opens in a new windowАннотация external link opens in a new window

9. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.Аннотация external link opens in a new window

10. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.Полный текст external link opens in a new windowАннотация external link opens in a new window

11. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105.Аннотация external link opens in a new window

12. Coustan DR, Carpenter MW, O'Sullivan PS, et al. Gestational diabetes: predictors of subsequent disordered glucose metabolism. Am J Obstet Gynecol. 1993;168:1139-1144.Аннотация external link opens in a new window

13. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.Аннотация external link opens in a new window

14. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.Полный текст external link opens in a new windowАннотация external link opens in a new window

15. Balk EM, Earley A, Raman G, et al. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann Intern Med. 2015;163:437-451.Полный текст external link opens in a new windowАннотация external link opens in a new window

16. Knowler WC, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677-1686.Аннотация external link opens in a new window

17. Hemmingsen B, Sonne DP, Metzendorf MI, et al. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;(5):CD012204.Полный текст external link opens in a new windowАннотация external link opens in a new window

18. Holman RR, Haffner SM, McMurray JJ, et al; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463-1476.Аннотация external link opens in a new window

19. McMurray JJ, Holman RR, Haffner SM, et al; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477-1490.Аннотация external link opens in a new window

20. Cohen RM. A1C: does one size fit all? Diabetes Care. 2007;30:2756-2758.Полный текст external link opens in a new windowАннотация external link opens in a new window

21. Jørgensen ME, Bjerregaard P, Borch-Johnsen K, et al. New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations? J Clin Endocrinol Metab. 2010;95:E333-E336.Полный текст external link opens in a new windowАннотация external link opens in a new window

22. Mostafa SA, Khunti K, Webb DR, et al. A comparison of performance from using two HbA1c cut-points (a ‘rule-in, rule-out’ spectrum) and one HbA1c cut-point to detect type 2 diabetes in a multi-ethnic cohort. Diabetologia. 2010;53(suppl 1):S86.Полный текст external link opens in a new window

23. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005 Sep;28(9):2289-304.Полный текст external link opens in a new windowАннотация external link opens in a new window

24. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800-811.Аннотация external link opens in a new window

25. US Preventive Services Task Force. Screening for gestational diabetes mellitus. October 2014. http://www.uspreventiveservicestaskforce.org/ (last accessed 17 July 2017).Полный текст external link opens in a new window

26. US Preventive Services Task Force. Abnormal blood glucose and type 2 diabetes mellitus: screening. October 2015. http://www.uspreventiveservicestaskforce.org/ (last accessed 17 July 2017).Полный текст external link opens in a new window

27. Hansen MB, Jensen ML, Carstensen B. Causes of death among diabetic patients in Denmark. Diabetologia. 2012;55:294-302.Аннотация external link opens in a new window

28. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720-1732.Полный текст external link opens in a new windowАннотация external link opens in a new window

29. Desai JR, Vazquez-Benitez G, Xu Z, et al. Who must we target now to minimize future cardiovascular events and total mortality? Lessons from the surveillance, prevention and management of diabetes mellitus (SUPREME-DM) cohort study. Circ Cardiovasc Qual Outcomes. 2015;8:508-516.Полный текст external link opens in a new windowАннотация external link opens in a new window

30. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174:773-785.Аннотация external link opens in a new window

31. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740-751.Аннотация external link opens in a new window

32. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36:1304-1311.Полный текст external link opens in a new windowАннотация external link opens in a new window

33. Sherifali D, Bai JW, Kenny M, et al. Diabetes self-management programmes in older adults: a systematic review and meta-analysis. Diabet Med. 2015;32:1404-1414.Аннотация external link opens in a new window

34. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med. 2015;163:848-860.Полный текст external link opens in a new windowАннотация external link opens in a new window

35. Fisher L, Hessler D, Glasgow RE, et al. REDEEM: a pragmatic trial to reduce diabetes distress. Diabetes Care. 2013;36:2551-2558.Полный текст external link opens in a new windowАннотация external link opens in a new window

36. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-65.Аннотация external link opens in a new window

37. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.Полный текст external link opens in a new windowАннотация external link opens in a new window

38. Gerstein HC, Miller ME, Genuth S, et al; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818-828.Аннотация external link opens in a new window

39. Patel A, MacMahon S, Chalmers J, et al; The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.Полный текст external link opens in a new windowАннотация external link opens in a new window

40. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.Полный текст external link opens in a new windowАннотация external link opens in a new window

41. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59.Полный текст external link opens in a new windowАннотация external link opens in a new window

42. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.Полный текст external link opens in a new windowАннотация external link opens in a new window

43. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-1903.Полный текст external link opens in a new windowАннотация external link opens in a new window

44. Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.Аннотация external link opens in a new window

45. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005;28:601-631.Аннотация external link opens in a new window

46. Elam MB, Ginsberg HN, Lovato LC, et al; ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2:370-380.Аннотация external link opens in a new window

47. Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014;312:155-161.Аннотация external link opens in a new window

48. Bibbins-Domingo K; US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836-845.Полный текст external link opens in a new windowАннотация external link opens in a new window

49. US Food and Drug Administration (FDA). Information for consumers (drugs): use of aspirin for primary prevention of heart attack and stroke. June 2014. http://www.fda.gov/ (last accessed 17 July 2017).Полный текст external link opens in a new window

50. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2960-2984.Полный текст external link opens in a new windowАннотация external link opens in a new window

51. Bolen S, Tseng E, Hutfless S, et al. Diabetes medications for adults with type 2 diabetes: an update. Comparative Effectiveness Reviews, no. 173. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016.Полный текст external link opens in a new windowАннотация external link opens in a new window

52. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431-1437.Полный текст external link opens in a new windowАннотация external link opens in a new window

53. US Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. April 2016. http://www.fda.gov/ (last accessed 17 July 2017).Полный текст external link opens in a new window

54. Gross JL, Kramer CK, Leitão CB, et al; for the Diabetes and Endocrinology Meta-analysis Group (DEMA). Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011;154:672-679.Аннотация external link opens in a new window

55. Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19:524-536.Аннотация external link opens in a new window

56. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206.Аннотация external link opens in a new window

57. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71.Полный текст external link opens in a new windowАннотация external link opens in a new window

58. European Medicines Agency (EMA). Questions and answers on the suspension of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim). September 2010. http://www.ema.europa.eu/ (last accessed 17 July 2017).Полный текст external link opens in a new window

59. Bach RG, Brooks MM, Lombardero M, et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2013;128:785-794.Полный текст external link opens in a new windowАннотация external link opens in a new window

60. US Food and Drug Administration. Pioglitazone-containing medicines: drug safety communication - updated FDA review, increased risk of bladder cancer. December 2016. https://www.fda.gov/ (last accessed 17 July 2017).Полный текст external link opens in a new window

61. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Jun 12 [Epub ahead of print].Полный текст external link opens in a new windowАннотация external link opens in a new window

62. Cherney DZ, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:610-621.Аннотация external link opens in a new window

63. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.Аннотация external link opens in a new window

64. US Food and Drug Administration (FDA). FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). June 2016. https://www.fda.gov/ (last accessed 17 July 2017).Полный текст external link opens in a new window

65. US Food and Drug Administration (FDA). FDA drug safety communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). May 2017. https://www.fda.gov/ (last accessed 17 July 2017).Полный текст external link opens in a new window

66. European Medicines Agency (EMA). SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. February 2017. http://www.ema.europa.eu (last accessed 17 July 2017).Полный текст external link opens in a new window

67. Medicines and Healthcare products Regulatory Agency. MHRA drug safety update: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes). March 2017. https://www.gov.uk/ (last accessed 17 July 2017).Полный текст external link opens in a new window

68. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.Полный текст external link opens in a new windowАннотация external link opens in a new window

69. Scirica BM, Bhatt DL, Braunwald E, et al; the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.Аннотация external link opens in a new window

70. White WB, Cannon CP, Heller SR, et al; the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-1335.Аннотация external link opens in a new window

71. Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164:705-714.Аннотация external link opens in a new window

72. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.Полный текст external link opens in a new windowАннотация external link opens in a new window

73. Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374:1145-1154.Аннотация external link opens in a new window

74. Nielsen GL, Møller M, Sørensen HT. HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care. 2006;29:2612-2616.Полный текст external link opens in a new windowАннотация external link opens in a new window

75. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. August 2015. http://www.nice.org.uk/ (last accessed 17 July 2017).Полный текст external link opens in a new window

76. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368:1613-1624.Полный текст external link opens in a new windowАннотация external link opens in a new window

77. Bodenheimer T, Wagner E, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model. JAMA. 2002;288:1775-1779.Аннотация external link opens in a new window

78. Shojania KG, Ranji, SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta regression analysis. JAMA. 2006;296:427-440.Аннотация external link opens in a new window

79. McLean DL, McAlister FA, Johnson JA, et al. A randomized controlled trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists - hypertension (SCRIP-HTN). Arch Intern Med. 2008;168;2355-2361.Полный текст external link opens in a new windowАннотация external link opens in a new window

80. O’Connor PJ, Sperl-Hillen JM, Rush WA, et al. Impact of electronic health record clinical decision support on diabetes care: a randomized trial. Ann Fam Med. 2011;9:12-21.Полный текст external link opens in a new windowАннотация external link opens in a new window

81. Margolis KL, O'Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721-1728.Полный текст external link opens in a new windowАннотация external link opens in a new window

82. Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-1509.Полный текст external link opens in a new windowАннотация external link opens in a new window

83. Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial. J Am Coll Cardiol. 2016;67:353-361.Аннотация external link opens in a new window

84. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.Аннотация external link opens in a new window

85. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-2257.Аннотация external link opens in a new window

86. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405-415.Аннотация external link opens in a new window

87. US Food and Drug Administration (FDA). FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. May 2015. http://www.fda.gov/ (last accessed 17 July 2017).Полный текст external link opens in a new window

88. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.Полный текст external link opens in a new windowАннотация external link opens in a new window

89. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567-1576.Аннотация external link opens in a new window

90. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641-651.Аннотация external link opens in a new window

91. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36:2175-2182.Полный текст external link opens in a new windowАннотация external link opens in a new window

92. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240-2249.Полный текст external link opens in a new windowАннотация external link opens in a new window

93. Halperin F, Ding SA, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014;149:716-726.Полный текст external link opens in a new windowАннотация external link opens in a new window

94. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695-704.Аннотация external link opens in a new window

95. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304:649-656.Полный текст external link opens in a new windowАннотация external link opens in a new window

96. Centers for Disease Control (CDC). State-specific trends in chronic kidney failure - United States, 1990-2001. MMWR Morb Mortal Wkly Rep. 2004;53:918-920.Аннотация external link opens in a new window

97. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27:1879-1884.Аннотация external link opens in a new window

98. Barrett-Connor EL, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA. 1991;265:627-631.Аннотация external link opens in a new window

99. Simpson TC, Weldon JC, Worthington HV, et al. Treatment of periodontal disease for glycaemic control in people with diabetes mellitus. Cochrane Database Syst Rev. 2015;(11):CD004714.Полный текст external link opens in a new windowАннотация external link opens in a new window

100. Bascones-Martinez A, Matesanz-Perez P, Escribano-Bermejo M, et al. Periodontal disease and diabetes: review of the literature. Med Oral Patol Oral Cir Bucal. 2011;16:e722-e729.Полный текст external link opens in a new windowАннотация external link opens in a new window

101. Pathak RD, Schroeder EB, Seaquist ER, et al. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005-2011. Diabetes Care. 2016;39:363-370.Аннотация external link opens in a new window

102. Beaulieu N, Cutler D, Ho K, et al. The business case for diabetes disease management for managed care organizations. Forum Health Econ Policy. 2006;9:Article 1.Полный текст external link opens in a new window

103. Rustad JK, Musselman DL, Nemeroff CB. The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology. 2011;36:1276-1286.Аннотация external link opens in a new window

104. Pamidi S, Tasali E. Obstructive sleep apnea and type 2 diabetes: is there a link? Front Neurol. 2012;3:126.Полный текст external link opens in a new windowАннотация external link opens in a new window

105. Shaw JE, Punjabi NM, Naughton MT, et al. The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. Am J Respir Crit Care Med. 2016;194:486-492.Аннотация external link opens in a new window

106. Martínez-Cerón E, Barquiel B, Bezos AM, et al. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes: a randomized clinical trial. Am J Respir Crit Care Med. 2016;194:476-485.Аннотация external link opens in a new window

107. Norris SL, Nichols PJ, Caspersen CJ, et al. Increasing diabetes self-management education in community settings: a systematic review. Am J Prev Med. 2002;22:39-66.Аннотация external link opens in a new window

108. Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015;38:1372-1382.Полный текст external link opens in a new windowАннотация external link opens in a new window

109. Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol. 1994;13:39-46.Аннотация external link opens in a new window

110. Young LA, Buse JB, Weaver MA, et al; Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial. JAMA Intern Med. 2017;177:920-929.Аннотация external link opens in a new window

111. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. May 2017. https://www.nice.org.uk/ (last accessed 17 July 2017).Полный текст external link opens in a new window

112. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147:578-581.Полный текст external link opens in a new windowАннотация external link opens in a new window

113. Malanda UL, Welschen LM, Riphagen II, et al. Self monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012;(1):CD005060.Полный текст external link opens in a new windowАннотация external link opens in a new window

114. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.Полный текст external link opens in a new windowАннотация external link opens in a new window

115. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.Полный текст external link opens in a new windowАннотация external link opens in a new window

Использование этого контента попадает под действие нашего заявления об отказе от ответственности